Try our Advanced Search for more refined results
Life Sciences - January, 2013
253 articles
- J&J Vaginal Mesh Plaintiff Says She Was Used As Guinea Pig
- Merck & Cie Wins $11.6M Over Acella's Supplements Marketing
- FTC Chief Leibowitz To Exit Agency In February
- P&G Gets Probiotic False Ad Action Pared
- DePuy Exec Called Hip Implant Study 'Suicide,' Jury Hears
- MAP Pharma Investor Sues To Stop Allergan's $958M Buy
- Device Makers Balk At Medicare Bidding Expansion
- Merck Shareholders Win Cert. In Vioxx Stock Fraud MDL
- Pfizer Ducks False Ad Suit Over Immune Supplement
- 2nd Circ. Upholds Merck Win In Bellwether Fosamax Trial
- Purdue Hits 2 Generics Makers With OxyContin Patent Suits
- Stryker Hip Implant Litigation Consolidated In Bergen County
- Ciba Knocks Out O2 Optix Contact Lens Injury Suit
- FCC Approves More Flexible Experimental Device Rules
- EU Says J&J, Novartis Pay-For-Delay Breached Antitrust Laws
- Determining Insurance Coverage In Food-Recall Disputes
- Watson Can't Prove Rapamune Patent Invalid, Judge Says
- JPML To Mull Novel Bankruptcy Shift In Meningitis Cases
- Krill Oil Co. Says Rivals Infringe Patent In ITC Suit
- FDA OKs Isis Orphan Drug Amid Shareholder's Safety Suit
- BMS, Sanofi Can't Shake FCA Suit Over Plavix Marketing
- AMA, AARP Back FTC In Pay-For-Delay Antitrust Fight
- NJ Judge OKs $8.1M Par Securities Settlement For Now
- DePuy CEO Testifies On Aussie Pullout In Hip Implant Suit
- Allergan, Duke Get Generic Lash-Growth Treatments Blocked
- French Watchdog Pulls Bayer Acne Drug Over Clotting Risk
- FDA Official Says Off-Label Ruling Won't Limit Enforcement
- McDermott Slams Suit Over Ex-Atty's Alleged IP Theft
- Discovery In J&J FCA Suit Was Too Narrow, 1st Circ. Hears
- Seeking Insurance Coverage For FDA Inspections Under FSMA
- Skadden Reps JLL Partners Unit In Medical Tech Buys
- Morgan Lewis Picks Up McDermott PE Pro
- Fed. Circ. To Mull Whether USPTO's Patent Term Math Adds Up
- Duane Morris Bolsters IP Group With Locke Lord Veteran
- Zinc Evidence Belongs In P&G Fixodent Case, 11th Circ. Told
- Drug Misbranding Investigations Remain Top Priority: DOJ
- Bristol-Myers, Sanofi Topple Plavix False Marketing Suit
- Lilly Fights Cymbalta 'Brain Zaps' Suit, Saying It Warned Docs
- Cephalon, SciMedica Can't Derail TCPA Class Action
- Generic Medical Foods Not Identical To Pamlab's, Suits Say
- Apotex Strikes Licensing Deal To Settle Pennsaid IP Row
- Pharma Exec Criminal Convictions And HHS Program Bans
- Genetically Modified Food Can Feed The Planet
- Fed. Circ. Upholds Allergan Win Over Lumigan Patent
- DePuy Hip Implant's Failure Rate 'Striking,' Jury Told
- FCA Expansion Fight May Land In High Court
- 3rd Circ. Says Pa. Fen-Phen Suit Barred By Earlier MDL Deal
- Sanofi, Bristol-Myers Defeat Plavix Failure-To-Warn Suit
- Europe To Review Blood Clot Risks In Contraceptives
- Judge Freezes Assets Of Execs Tied To Meningitis Outbreak
- Myriad Can't Patent Cancer Genes, ACLU Tells High Court
- Eye Med Distributor's $100M Suit Barred By Deal, Akorn Says
- Pfizer Sues Wockhardt To Block Lyrica Generic
- And Now A Word From The Panel ...
- Consumers Urge Wider Recall In Ranbaxy Glass Shards Action
- How Already V. Nike Could Impact Hatch-Waxman Cases
- AstraZeneca Escapes Medco FCA Kickbacks Suit
- Health Groups Accuse Device Firms Of Shirking $30B ACA Tax
- FDA OKs Merck's OTC Treatment For Overactive Bladder
- Nexium MDL Judge Scolds Attys For Lead Counsel 'Squabble'
- Sandoz Generics Claims Survive, Despite Post-Mensing Trend
- FDA Panel Votes For Tougher Controls On Hydrocodone
- J&J Unit DePuy Knew Of Hip Implant Defect, Jury Hears
- AbbVie Sues Sun Pharmaceutical Over Generic Zemplar
- McKesson, Sales Reps Reach $1.2M Accord In FLSA Action
- Glenmark Sues GSK To Invalidate Antibiotic Cream Patents
- Banker Accused Of Aiding Olympus' $2B Plot Gets Bail
- US V. Takeda Will Be Useful In Off-Label Promotion Cases
- FDA Wise To Duck High Court Off-Label Ruling, Attys Say
- Pay-For-Delay Antitrust Test Sets Bar Too High: FTC Official
- US Pushes Supreme Court To Reverse Design Defect Ruling
- Kirkland IP Pro Heads to Sheppard Mullin
- Pa. Devicemaker Sues Bard To Overturn USPTO Decision
- 7th Circ. Asked To Revive Walgreen, Par RICO Suit
- NuVasive Noncompete Too Restrictive, Device Seller Says
- SEC Urges 2nd Circ. To Uphold Debarment For Takeda Exec
- Sargon Enterprises V. USC: A Step Toward Daubert
- HIPAA Update Will Shake Up Marketing, Fundraising Efforts
- Novartis Faces Probe Over Trade With Iran
- Roche Accuses Accutane Judge Of 'One-Sided' Remarks
- 3rd Circ. Shuts Down Ethypharm Antitrust Suit Against Abbott
- FTC Tells Justices Pay-For-Delay 'Presumptively Unlawful'
- Dem. Wants Repeal Of $500M Amgen 'Fiscal Cliff' Gift
- Drugmaker, FDA Agree On Terms To Fix Production Issues
- Watson Boosts Women's Health Holdings In $305M Uteron Deal
- Life Sciences Group Of The Year: Weil Gotshal
- Schoeman Expands To New Digs In 5th Ave. Landmark
- Ex-McDermott Atty Fed Client IP To Family Co., Suit Says
- The Broad Reach Of New 'Failure-To-Warn-FDA' Claims
- Allergan Puts Up $958M For Migraine Treatment Maker
- DC Circ. Sides With DEA On Marijuana Classification
- GSK Says E-Discovery Co.'s CEO Is Holding Data Hostage
- Attys Agree To $143M Fee Split In $2.3B Avandia MDL
- FDA Approves Allergan's Botox For Overactive Bladders
- J&J Foresaw 40% Failure Rate In Hip Implants, Doc Shows
- Impax Denied Parkinson's Drug Approval Over Plant Issues
- Novel Infringed Braintree's Laxative Patent, Judge Rules
- Life Sciences Group Of The Year: Sidley Austin
- Dr. Reddy's Generic Found Not To Infringe Lunesta Patent
- Lone Pine's Impact On Pharma Products Litigation
- Grant & Eisenhofer Sued Over Share Of $84M Abbott Award
- Noncounty Plaintiffs Booted From Ill. J&J Suits
- Alzheimer's Drug Claims Already Failed Once, Pfizer Says
- Europe Moves To Suspend Merck Cholesterol Drug
- Life Technologies Feeds LBO Rumors
- FDA Defends Approval Of Generic Acetaminophen OD Drug
- Judge Won't Nix Apotex Suit Over Drugmaking IP
- Lawmakers Vow To Revive Pay-For-Delay Deal Ban
- FDA Clarifies Rules For Combination Medical Products
- Life Sciences Group Of The Year: Skadden
- US Calls OxyContin FCA Suit 'Parasitic'
- Stryker Offers $771M For Hong Kong Orthopedics Maker
- FDA Rule May Be Lose-Lose Scenario For Metal-Hip Makers
- FTC Pay-For-Delay Stats Show Androgel Stakes Are High
- Swiss Pharma Co. Shakes Suit Over $120M Supply Contract
- J&J, Boston Scientific Escape Off-Label Marketing Suit
- Life Sciences Group Of The Year: Fish & Richardson
- Roche's Win Over $12M Accutane Judgments Stands In NJ
- Covidien Dodges Surgical Stapling Class Claims For Now
- Cohen Milstein Survives DQ Bid In Lipitor MDL
- Actelion Says Antitrust Law Can't Make It Sell To Rivals
- Next On SCOTUS: A Significant Case For Drug Manufacturers
- OneBeacon Must Defend Vitamin Co. In Distribution Fight
- Stryker Field Service Reps Win Class Cert. In FLSA Suit
- NFL Doc Blames Smith & Nephew For $2.2M Malpractice Suit
- Life Sciences Group Of The Year: Covington & Burling
- Pfizer Says Off-Label Marketing FCA Suit Falls Short
- Hemispherx Lied About Immune Disorder Drug, Investor Says
- High Court Mulls Limits Of US Agency Powers In FCC Row
- NuAire, Merrill Agree To Drop Incubator Recall Fight
- Pfizer Settles Chantix Suit Slated For Bellwether Trial
- Smith & Nephew's $85M Patent Win Revived By Fed. Circ.
- Merck Says Fosamax Femur Fracture Claims Are Preempted
- Fighting Through The Storm: Employment Law Year In Review
- Where Calif. Stands On A New Product Liability Trend
- New Tests Set To Turn Food Litigation On Its Head
- White House Pressed Again Over Doc Payment Sunshine Rule
- Patheon Says JV Partner Can't Sue Over $255M Acquisition
- GSK's Generic Flonase Antitrust Deal Gets Green Light
- Biotronik Escapes Suit Over Defective Defibrillators
- Supplement Co. Can't Sue FDA Officer Over Product Seizure
- 6th Circ. Asked To Revive Suits Alleging Generic Reglan Harm
- Noteworthy Product Liability Decisions Of 2012: Part 2
- Skowron Fights $10.2M Morgan Stanley Payment At 2nd Circ.
- Hatch-Waxman Safe Harbor Murky After High Court Rejection
- 9th Circ. Further Muddies Case For Device Preemption
- Cigna Sued Over Denials On Heart Monitoring Device
- Chinese Bidder Draws Closer To Complete Genomics Buy
- GSK To Shell Out $21.5M To Exit Wellbutrin Antitrust Suit
- Top Court Won't Consider Mylan's Patent Battle Over Amrix
- FDA Warns St. Jude Over Production Of Heart Device
- Fla. Hospital Again Denied Cert. In $867M Drug Antitrust Suit
- Apotex Challenge To Abilify IP Won't Get High Court Hearing
- Synthes Owes $1.2M In Surgical Tool Deal, Suit Says
- Justices Invite SG's Opinion In Pfizer Asbestos Case
- Covington & Burling Opens 3rd Asia Outlet In Shanghai
- FAQs About Mass. Medical Marijuana Law
- Ala. Ruling May Mark Post-Mensing Trend For Brand Liability
- SAC Unit Will Try To Shake Insider Trading Claims
- J&J Exec Says Vaginal Mesh Product Passed Safety Tests
- 4th Circ. Backs Dismissal of Takeda Whistleblower Suit
- EU Says No New Evidence Of Clot Risks In Contraceptives
- Brand-Name Makers Can Face Generic-Drug Suits: Ala. Court
- Roche Wants 40 Accutane Suits Junked For Lack Of Experts
- FDA Yanks Rule Shielding Docs In Misconduct Inquiries
- J&J Hit With Five Suits Over Tylenol In Pa. Court
- BioMimetic Triumphs Over Investors' Fraud Class Action
- Pharmaceutical Product Switching: Antitrust Pitfalls
- Herbalife Defends Against Ackman's 'Pyramid Scheme' Attack
- J&J Failed To Warn Of Vaginal Mesh Risks, NJ Jury Told
- 9th Circ. Revives Paraplegic Man's Medtronic Pain Pump Suit
- Teva Wants Strict FDA Review For Biogen's Rival MS Drug
- New Civil Litigation Firm NastLaw Launches In Philly
- FDA Orders Cuts To Sleep-Aid Dosages Over Car Crash Risks
- The Split On FDA Requirement Of Graphic Smoking Warnings
- FDA Instructs Opioid-Drug Makers On Abuse Deterrents
- SEC Opens Herbalife Probe Following Pyramid Scheme Barb
- Ex-InterMune CEO Sues HHS Over 5-Year Program Ban
- State Suits To Protect Citizens Not Class Actions: 2nd Circ.
- Cooperator In Whitman Insider Trading Case Dodges Prison
- Fed. Circ. Mulls Discovery Rights In Patent Re-Exams
- Purdue, Ranbaxy Settle IP Fight Over Generic Oxycontin
- ViroPharma Denied Block On Generic Vancocin Approval
- McDermott Adds Greenberg Securities, Life Sciences Partner
- Rite Aid, Others Jump Into Pay-For-Delay MDL Against Pfizer
- Sequenom Pushes Fed. Circ. To Bar Ariosa Prenatal Test
- Allergan Sues To Stop Generic Eyelash-Growth Drug
- FDA Weighs St. Jude's Promise Of Durata Production Fixes
- Davis Wright Adds Ex-Goodwin Procter Patent Atty In SF
- Forest Labs Skirts Sanctions In Lexapro, Celexa Suicide MDL
- Avon Hit With False Ad Suit Over Anti-Aging Product Claims
- Noteworthy Product Liability Decisions Of 2012: Part 1
- Elan Investors Hit SAC With Insider Trading Class Action
- Cordis Case May Open Door To Discovery In Patent Re-Exams
- Judge Tosses Cooper Co. Investor Suit Over Lens Recall
- Pfizer, Investors Lose Sanctions Bids In Arthritis Drugs Case
- J&J Diabetes Drug Effective But Carries Risks, FDA Says
- SEC's Case Against Ex-Home Diagnostics CEO Reopened
- WilmerHale Welcomes Back Life Sciences Pro
- DOJ Wants Trustee In Meningitis Pharmacy Bankruptcy
- Fosamax MDL Plaintiff Slams Jury Instructions At 2nd Circ.
- McDermott Adds 2 Ex-Epstein Health Care Attys In DC
- Bayer Yaz Patents Are Obvious, Sandoz Tells Fed. Circ.
- Dykema Opens Minneapolis Office With IP, Corporate Focus
- Medtronic Wants Off-Label Marketing FCA Suit Junked
- Texas Could Lead The Nanotech Revolution
- Pros And Cons Of Proposed Medicare Smart Cards
- Fresenius Seeks To Trim FCA Suit Over Medicare Bills
- UnitedHealth Takes Reimbursement Fight To Supreme Court
- Health Spending Still Growing, But Slowly, Report Says
- Top Court's Denial Won't Be Last Word On Claim Construction
- Novartis Sues Alvogen To Block Generic Dementia Patch
- ITC Nixes Invisalign IP Enforcement Action
- FTC Often Forces Fixes In Pharma Probes, Stats Show
- Justices Weigh Class Action Fairness Act's Removal Power
- White House Pressed To Approve Doc Payment Sunshine Rule
- King Pharma Says Patent Deal Didn't Bar Skelaxin Generic
- Supreme Court Won't Review Medicare Reimbursement Denials
- NIH Stem Cell Research Funding Won't Get High Court Review
- Covington Guides Illumina In $350M Buy Of Verinata
- 'Fungi-Nail' False Ad Suit Will Stay In Federal Court
- Mass Gov. Proposes Overhaul To Compounding Oversight
- Hospira Drug Shortage Suit Must Be Revived, 11th Circ. Told
- Ind. Gets More Time To Mull $48M Healthpoint FCA Deal
- MIT Sues Shire Over Cell-Growing Mesh IP
- Pentagon Can Unilaterally Cap Tricare Drug Rates: DC Circ.
- Pfizer, Endo Pay $50M To Settle Drug Price Inflation Claims
- Whistleblower Pushes To Revive Boston Scientific FCA Suit
- Watchdog Blasts 5-Hour Energy Maker Over 'Crash' Claim
- Foley Lands 29-Year McDermott Vet For Health M&A Team
- Medtronic Stole Heart Surgery Device IP, Patent Holder Says
- Wyeth Ends Employees' ERISA Action With $2M Deal
- Gov't Loses Bid To Seal Docs In FDA Email Spying Case
- 5th Circ. Lets Chubb Off Hook In $20M Diet Aid Coverage Row
- Whistleblower Can't Fight Amgen's $612M Aranesp Deal: Judge
- Epstein Becker Welcomes Health Care Pro Back To Firm
- Life Sciences Forecast For Middle East And North Africa
- More Gatekeeper Roles And Obligations For Trial Courts
- Forest Labs, Glenmark End Blood Pressure Drug IP Fight
- Greenwich Sues To Duck Cleanup Costs At NJ Becton Site
- SAC, Founder Face Investor Suit Over Insider Trading Scandal
- Warburg Pincus Puts Up $195M For Specialty Drug Co.
- J&J Wins Rapid Approval Of Specialized TB Drug
- Hughes Hubbard Lures Ex-Shook Hardy Product Liability Vet
- Isis Accused Of Hiding Cholesterol Drug's Safety Risks
- Ranbaxy Foils Mylan's Challenge To Valsartan Exclusivity
- Recent Past Is Prologue To Life Sciences Regulation
- How Caronia Could Reshape Government Investigations
- Life Sciences Cases To Watch In 2013
- Life Sciences Regulation To Watch In 2013
- IP Cases To Watch In 2013
- Competition Regulation And Legislation To Watch In 2013
- Law360 Selects Top Practice Groups Of The Year